IP Library › Granted Patent US 12,680,090
Granted Patent B1
US 12,680,090 · App. 18/520,769 · Granted Jul 14, 2026

Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and modified biomolecules

Inventors: David Wilson (Pittsburgh, PA); Jennifer L. Poole (Delmont, PA); Jeremy P. Walker (Oakmont, PA)
Assignee: TELEDYNE FLIR DEFENSE, INC.
C12N9/16C12Y301/08001A61K38/465
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,680,090
App. No.
18/520,769
Filed
Nov 28, 2023
Granted
Jul 14, 2026
Kind
B1
Examiner
PAK, YONG D
Art Unit
1652
USPC
424/94.3
Abstract

Pharmaceutical formulations that can include at least one genetically modified OPH enzyme are provided. Methods for treating chemical warfare agent exposure are also provided. Modified biomolecules are also provided.

Claims (19)

1 . A pharmaceutical formulation comprising a composition and a pharmaceutically-acceptable buffer, wherein the composition comprises:

a first organophosphorus hydrolase (OPH) protein:polymer conjugate that comprises:

at least a first genetically-modified OPH YT protein; and

at least a first polymer produced via controlled radical polymerization from a molecular initiator, wherein the molecular initiator is conjugated to the first genetically-modified OPH YT protein and the polymer comprises polyethylene glycol methyl-ethyl methacrylate (PEGMA) chain;

wherein an in vivo k cat /k m of the protein:polymer conjugate is >1×10 7 for at least one G-series chemical warfare agent.

2 . The pharmaceutical formulation of claim 1 , wherein the protein:polymer conjugate has a molecular weight in a range of 175 kDa to 222 kDa.

3 . The pharmaceutical formulation of claim 1 , wherein the formulation further comprises a second OPH protein:polymer conjugate,

wherein the second OPH protein:polymer conjugate comprises at least a second, genetically modified OPH protein, selected from the group consisting of OPH YT protein, OPH C23 protein, and OPH IVH3 protein.

4 . The pharmaceutical formulation of claim 1 , wherein the molecule initiator is N-hydroxysuccinimide-tetra-ethylene-glycol bromide (NHS-TEG-Br).

5 . A pharmaceutical formulation comprising a composition and a pharmaceutically-acceptable buffer, wherein the composition comprises:

a first organophosphorus hydrolase (OPH) protein:polymer conjugate that comprises:

at least a first genetically-modified OPH YT protein; and

at least a first polymer conjugated thereto, the polymer comprising a polyethylene glycol methyl-ethyl methacrylate (PEGMA) chain;

wherein an in vivo k cat /k m of the protein:polymer conjugate is >1×10 7 for at least one G-series chemical warfare agent.

6 . The pharmaceutical formulation of claim 1 , wherein the protein:polymer conjugate has a molecular weight in a range of 54 kDa to 130 kDa.

7 . The pharmaceutical formulation of claim 1 , wherein the protein:polymer conjugate has a molecular weight in a range of 130 kDa to 175 kDa.

8 . The pharmaceutical formulation of claim 5 , wherein the protein:polymer conjugate has a molecular weight in a range of 54 kDa to 130 kDa.

9 . The pharmaceutical formulation of claim 5 , wherein the protein:polymer conjugate has a molecular weight in a range of 130 kDa to 175 kDa.

10 . The pharmaceutical formulation of claim 5 , wherein the protein:polymer conjugate has a molecular weight in a range of 175 kDa to 222 kDa.

Assignments (3)
CERTIFICATE OF CONVERSION Recorded Jul 17, 2026
From: TELEDYNE FLIR DEFENSE, INC.
To: TELEDYNE FLIR DEFENSE, LLC
Reel/Frame 075999/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2024
From: WILSON, DAVID; POOLE, JENNIFER L.; WALKER, JEREMY P.
To: FLIR DETECTION, INC.
Reel/Frame 067021/0704 →
CHANGE OF NAME Recorded Apr 5, 2024
From: FLIR DETECTION, INC.
To: TELEDYNE FLIR DETECTION, INC.
Reel/Frame 067026/0312 →
Continuity (3)
Continuation 17320192 · May 13, 2021
Division 15994621 · May 31, 2018
Provisional Application 62513330 · May 31, 2017
References Cited (29)
US 6541230B1 · Gordon et al. · 2003 [cited by applicant]
US 10260054B2 · Pegan et al. · 2019 [cited by applicant]
US 10301608B2 · Faushel et al. · 2019 [cited by applicant]
US 10363290B2 · Perlroth et al. · 2019 [cited by applicant]
US 20150376594A1 · Walker et al. · 2015 [cited by applicant]
US 20160009757A1 · Lihme · 2016 [cited by applicant]
US 20160184445A1 · Periroth et al. · 2016 [cited by applicant]
US 20160355792A1 · Pegan et al. · 2016 [cited by applicant]
WO 2000064539 · 2000 [cited by applicant]
WO 2001036665 · 2001 [cited by applicant]
WO 2015196106 · 2015 [cited by applicant]
Zhang et al., “Nanoscavenger Provides Long-Term Prophylactic Protection Against Nerve Agents in Rodents”, Science Translational Medicine Research Article and Supplemental Materials, Jan. 2, 2019, United States, 25 pages. [cited by applicant]
Andreopoulos et al., “Photoimmobilization of Organophosphorus Hydrolase within a PEG-Based Hydrogel”, Biotechnology and Bioengineering vol. 65, 1999, Germany, pp. 579-588. [cited by applicant]
Ashani et al. “Estimation of the Upper limit of Human Butyrylcholinesterase Dose Required for Protection Against Organophosphates Toxicity: A Mathematically Based Toxicokinetic Model”, Toxicological Sciences vol. 77. 20… [cited by applicant]
Ashani et al., “In Vitro Detoxification of Cyclosarin in Human Blood Pre-Incubated Ex Vivo with Recombinant Serum Paraoxonases”, Toxicology Letters, vol. 206, Sep. 2011, Netherlands, pp. 24-28. [cited by applicant]
Bigley et al., “Enzymatic Neutralization of the Chemical Warfare Agent VX: Evolution of Phosphotriesterase for Phosphorothiolate Hydrolysis”, Journal of the American Chemical Society vol. 135, 2013, United States, pp. 1… [cited by applicant]
Cherny et al., “Engineering V-Type Nerve Agents Detoxifying Enzymes Using Computationally Focused libraries”, ACS Chemical Biology vol. 8, 2013, United States, pp. 2394-2403. [cited by applicant]
Fishburn, The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics, Journal of Pharmaceutical Sciences vol. 97, No. 10, Oct. 2008, United States, pp. 4167-4183. [cited by applicant]
Goldsmith et al., “Catalytic Efficiencies of Directly Evolved Phosphotriesterase Variants with Structurally Different Organophosphorus Compounds in Vitro”, Archives of Toxicology vol. 90, 2016, Germany., pp. 2711-2724. [cited by applicant]
Hurst, “Medical Management of Chemical Casualties Handbook”, 5th Edition, U.S. Army Medical Research Institute of Chemical Defense, 2014, United States. 190 pages. [cited by applicant]
Lenz et al. , “Butyrylcholinesterase as a Therapeutic Drug for Protection Against Percutaneous VX”, Chemico-Biological Interactions vol. 187, 2010, Netherlands, pp. 249-252. [cited by applicant]
Lillie et al., “Potential Military Chemical/biological Agents and Compounds”, Army, Marine Corps, Navy, Air Force, Jan. 2005, United States, 318 pages. [cited by applicant]
Mumford et al, “Post-Exposure Therapy with Recombinant Human BuChE Following Percutaneous VX Challenge in Guinea-Pigs”, NIH Public Access Author Manuscript, published in Toxicology Letters vol. 206. Sep. 25, 2011, Nethe… [cited by applicant]
Novikov et al., “Improved Pharmacokinetics and Immunogenicity Profile of Organophosphorous Hydrolase by Chemical Modification with Polyethylene Glycol”, Journal of Controlled Release vol. 146, 2010, Netherlands, pp. 318… [cited by applicant]
Pisal et al,, “Delivery of Therapeutic Proteins”, NIH Public Access Author Manuscript, Published in Journal of Pharmaceutical Sciences vol. 99, Jun. 2010, United States, pp. 2557-2575. [cited by applicant]
Tsai et al., “Enzymes for the Homeland Defense⋅ Optimizing Phosphotriesterase for the Hydrolysis of Organophosphate Nerve Agents”, Biochemistry vol. 51, 2012, United States, pp. 6463-6475. [cited by applicant]
Wilson et al., “High-Throughout Functionalization of Organophosphate Scavenger Enzymes for Improved Pharmacokinetics and Warfighter Protection”, Flir Systems. Inc., 2016, United States, 1 page. [cited by applicant]
Studer, “Residue mutations and their impact on protein structure and function: detecting beneficial and pathogenic changes”, Biochem. J (2013), 449, 581-594. [cited by applicant]
Nanocs, 2013. [cited by applicant]